Table 1.

Description of HRT Trials.

Study	Length months	Type of Oestrogen	Progestin+ Addition of calcium*	Study Population	Outcome measure	Age (SD/range)
Alexandersen 1999 [12]	22	50-ug transdermal estradiol	+*	Healthy postmenopausal women with low BMD	BMD	65 (2.2)
Delmas 2000 [5]	24	Oral 1 mg estradiol	+*	Healthy >1 year postmenopausal women with normal BMD.	BMD	58 (5)
Gallagher 2001 [14]	36	Oral 0.625 mg conjugated estrogens	+*	Elderly women with normal bone density	BMD	72(± 4)
Cauley 2001 [4]	49	Oral 0.625 conjugated estrogen	+	Women with established coronary disease >5 years post menopause	MI or CHD	67
Herrington 2000 [6]	38	Oral 0.625 conjugated estrogen	+	Women with coronary arterial disease (CAD)	CAD Progression	66 (7.0)
Ishida 2001 [15]	12	Oral 0.625 conjugated estrogen.	+	Women with established osteoporosis.	BMD	70 (7.6)
Lindsay 1990 [13]	24	Oral 0.625 mg conjugated estrogen	+*	Postmenopausal women with 1+ vertebral fracture & low BMD	BMD	48 (1.0)
Lufkin 1992 [1]	12	Transdermal 0.1 mg 17β-estradiol	+	Postmenopausal white women with documented osteoporosis	BMD	64.8 (54.9 to 71.3)
Mosekilde 2000 [7]	60	Oral 1 mg or 2 mg estradiol	+	Healthy women 3–24 months post menopause	Fractures	50 (2.8)
PEPI 1996 [8]	36	Oral 0.625 mg conjugated estrogen	+	Healthy women 1–10 years post menopause normal BMD	BMD	56 (0.3)
Ravn 1999 [9]	48	Oral 0.625 conjugated estrogen or 2 mg estradiol	+	Healthy 6+ months postmenopausal women under 60 years	BMD	55
Recker 1999 [10]	42	0.3 mg conjugated estrogen	+*	Healthy women average BMD t-score-3.5 at femur	BMD	73 (5.0)
Wimalawansa 1998 [11]	48	Oral 0.625 conjugated estrogen	+*	Women with established osteoporosis (1+vertebral fracture)	BMD	65 (0.9)